Thompson Siegel & Walmsley LLC increased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 23.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 283,860 shares of the specialty pharmaceutical company's stock after buying an additional 53,701 shares during the quarter. Thompson Siegel & Walmsley LLC owned about 1.35% of ANI Pharmaceuticals worth $15,692,000 as of its most recent SEC filing.
A number of other hedge funds have also recently added to or reduced their stakes in ANIP. Pacer Advisors Inc. grew its stake in ANI Pharmaceuticals by 23,259.8% during the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company's stock worth $33,907,000 after buying an additional 565,910 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of ANI Pharmaceuticals by 159.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock valued at $33,101,000 after purchasing an additional 340,854 shares during the last quarter. abrdn plc purchased a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at approximately $13,155,000. Bank of Montreal Can purchased a new position in shares of ANI Pharmaceuticals in the 3rd quarter valued at approximately $13,043,000. Finally, Mizuho Markets Americas LLC purchased a new position in shares of ANI Pharmaceuticals in the 3rd quarter valued at approximately $11,670,000. Hedge funds and other institutional investors own 76.05% of the company's stock.
Insider Buying and Selling at ANI Pharmaceuticals
In other news, CFO Stephen P. Carey sold 7,500 shares of the company's stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the sale, the chief financial officer now owns 154,468 shares of the company's stock, valued at $8,617,769.72. This represents a 4.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Meredith Cook sold 400 shares of the company's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the sale, the vice president now directly owns 80,545 shares of the company's stock, valued at $5,100,914.85. The trade was a 0.49 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,700 shares of company stock valued at $610,201. Company insiders own 12.70% of the company's stock.
Wall Street Analyst Weigh In
Several research analysts have weighed in on the company. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a research note on Friday. They issued a "buy" rating and a $80.00 target price on the stock. Leerink Partners assumed coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 target price on the stock. Guggenheim lifted their target price on ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. StockNews.com upgraded ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Friday. Finally, HC Wainwright restated a "buy" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, ANI Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $79.75.
View Our Latest Stock Report on ANI Pharmaceuticals
ANI Pharmaceuticals Trading Up 3.0 %
ANIP stock traded up $1.86 during trading on Monday, reaching $64.35. 334,305 shares of the stock traded hands, compared to its average volume of 238,236. The business's 50 day moving average price is $58.40 and its 200-day moving average price is $58.06. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $70.81. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The firm has a market capitalization of $1.40 billion, a PE ratio of -117.00 and a beta of 0.63.
ANI Pharmaceuticals Profile
(
Free Report)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Further Reading
Before you consider ANI Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.
While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
